GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated February 11, 2026, reports transaction notifications for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The filing covers transactions executed on February 9 and February 10, 2026, primarily involving the acquisition of Ordinary Shares under the Company's Share Reward Plan and one sale of American Depositary Shares (ADS).
Key Financial Metrics and Transactions
The filing details specific share transactions rather than aggregate company financial performance. Key transaction metrics include:
- Share Acquisitions: Multiple executives acquired Ordinary Shares (ISIN: GB00BN7SWP63) at a price of £21.7918 per share on February 10, 2026, via the London Stock Exchange (XLON). Most transactions involved 12 shares (6 partnership, 6 matching), with one executive acquiring 10 shares.
- Share Sale: Diana Conrad, Chief People Officer, sold 10,000 ADS (ISIN: US37733W2044) at $59.1802 per share on February 9, 2026, via the New York Stock Exchange (XNYS).
- Company Financials: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It strictly reports individual insider trading activities required by regulatory disclosure rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine disclosure of insider transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs under the Share Reward Plan to assess alignment with company performance.
- Confirm the context of the 10,000 ADS sale by the Chief People Officer to determine if it was part of a pre-arranged trading plan.
- Review the company's latest Form 20-F or earnings release for actual financial performance metrics, as this Form 6-K does not contain them.
- Check the current market price of GSK Ordinary Shares and ADS to compare against the transaction prices reported (£21.7918 and $59.1802).